Vertaling van "trial long-term follow-up " (Frans → Nederlands) :

3 Ballard C, Hanney ML, Theodoulou M et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial.
3 Ballard C, Hanney ML, Theodoulou M et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term followup of a randomised placebo-controlled trial.

A Retrospective Analysis of Surgical Treatment in Patients With Symptomatic Hallux Rigidus: Long-Term Follow-Up The objective of this retrospective study was to analyze the long-term clinical outcomes and patient satisfaction of operative care in patients with symptomatic hallux rigidus.
A Retrospective Analysis of Surgical Treatment in Patients With Symptomatic Hallux Rigidus: Long-Term Follow-Up The objective of this retrospective study was to analyze the long-term clinical outcomes and patient satisfaction of operative care in patients with symptomatic halluxrigidus.

Trois études avec follow-up long dÊinhibiteurs sélectif de reuptake de sérotonine (selective serotonin reuptake inhibitors – SSRI), et dÊautres études avec des follow-up plus courts, ne montrent aucun effet de ces classes dÊantidépresseurs dans le sevrage tabagique.
Drie studies met lange follow-up van selectieve serotonine reuptake inhibitoren (SSRI) en andere studies met korte follow-up toonden geen effect van deze klasse van antidepressiva bij rookstop.

Les données issues d’une troisième étude à long terme appelée ADAPT (The Alzheimer's Disease Anti-inflammatory Prevention Trial) n’ont révélé aucune augmentation significative du risque cardiovasculaire associée à la prise biquotidienne de 200 mg de célécoxib par rapport au placebo.
Gegevens van een derde langetermijnstudie, ADAPT (Ziekte van Alzheimer anti-inflammatoire preventiestudie) lieten geen significant verhoogd cardiovasculair risico zien met celecoxib 200 mg tweemaal daags in vergelijking met placebo.

Les données d’une troisième étude à long terme, ADAPT (l’Alzheimer's Disease Anti-inflammatory Prevention Trial), n’ont pas révélé de risque cardiovasculaire significativement accru avec le célécoxib 200 mg deux fois par jour comparativement au placebo.
De gegevens van een derde langetermijnstudie, ADAPT (de Alzheimer’s Disease Anti-inflammatory Prevention Trial) wezen niet op een significant verhoogd cardiovasculair risico met celecoxib 200 mg tweemaal per dag in vergelijking met placebo.

Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.
Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. preventive services task force.

GC et al. Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial.
Aa GC et al. Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial.

21. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening.
20. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening.